
the staff of the Ridgewood blog
Continue reading Oral Antivirals Could Transform the Treatment of COVID-19
the staff of the Ridgewood blog
Continue reading Oral Antivirals Could Transform the Treatment of COVID-19
the staff of the Ridgewood blog
FOSTER CITY Calif, Gilead Sciences, Inc. (Nasdaq: GILD) today announced the initiation of two Phase 3 clinical studies to evaluate the safety and efficacy of remdesivir in adults diagnosed with COVID-19 (novel coronavirus). These randomized, open-label, multicenter studies will enroll approximately 1,000 patients at medical centers primarily across Asian countries, as well as other countries globally with high numbers of diagnosed cases, beginning in March. The studies will assess two dosing durations of remdesivir, administered intravenously. The initiation of these studies follows the U.S. Food and Drug Administration’s (FDA) rapid review and acceptance of Gilead’s investigational new drug (IND) filing for remdesivir for the treatment of COVID-19.